Literature DB >> 12490614

Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.

Takao Makino1, Yuichi Hattori, Naoyuki Matsuda, Hisao Onozuka, Ichiro Sakuma, Akira Kitabatake.   

Abstract

Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor blockers have been demonstrated to improve symptoms and prognosis in heart failure (HF). We compared the effects of ACE inhibition and AT1 receptor blockade on myocardial beta-adrenoceptor desensitization in rabbits with HF established 3 weeks after myocardial infarction (MI) with left circumflex coronary artery ligation. Rabbits with MI were randomized to no treatment, the ACE inhibitor temocapril (0.5 mg/kg/day) or AT1 receptor blocker valsartan (3 mg/kg/day). Echocardiographic examinations showed that, relative to rabbits with untreated MI, rabbits receiving temocapril or valsartan had a limitation of cardiac remodeling and prevention of the development of systolic dysfunction. Circulating plasma norepinephrine levels that were markedly elevated in MI animals were strongly inhibited by temocapril or valsartan therapy. beta-Adrenoceptor density, beta-adrenoceptor proportion showing high-affinity agonist binding, and basal and isoproterenol-stimulated adenylate cyclase activities were significantly reduced in MI rabbits. These defects were similarly reversed by temocapril or valsartan. Importantly, as found in human HF, myocardial protein levels of beta-adrenoceptor kinase 1 and G(i alpha) were significantly elevated in MI rabbits, suggesting that these molecules are contributing to the defects in myocardial beta-adrenoceptor signaling. The expression levels of these molecules were normalized equally by both treatments. The results suggest that pharmacologically different interventions in the renin-angiotensin system can equivalently improve the derangements in the beta-adrenoceptor signaling system in the failing heart. This may be important for the beneficial effects of these agents in HF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490614     DOI: 10.1124/jpet.102.040956

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits.

Authors:  Ming Yu; Jody Bozek; Mary Guaraldi; Mikhail Kagan; Michael Azure; Simon P Robinson
Journal:  J Nucl Cardiol       Date:  2010-03-26       Impact factor: 5.952

2.  Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction.

Authors:  Harjot K Saini; Qiming Shao; Sorin Musat; Nobuakira Takeda; Paramjit S Tappia; Naranjan S Dhalla
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

3.  Changes in β-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.

Authors:  Rajat Sethi; Qiming Shao; Bin Ren; Harjot K Saini; Nobuakira Takeda; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

4.  Cardiac fibroblasts inhibit β-adrenoceptor-dependent connexin43 expression in neonatal rat cardiomyocytes.

Authors:  A Salameh; H Djilali; K Blanke; J Gonzalez Casanova; S von Salisch; A Savtschenko; S Dhein; I Dähnert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-03       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.